

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- _____ is a selective BRAF inhibitor that has demonstrated similar activity to vemurafenib with a confirmed response rate of approximately 50% in the Phase III BREAK-3 trial comparing it to dacarbazine for patients with previously untreated, unresectable Stage III/IV BRAF V600E-mutated melanoma.
 - Dabrafenib
 - Ipilimumab
 - Trametinib
 - Anti-PD-1 antibody
- The Phase III METRIC trial evaluated chemotherapy versus a selective MEK inhibitor called _____ for patients with BRAF-mutant advanced or metastatic melanoma.
 - Vemurafenib
 - Trametinib
 - Ipilimumab
- A planned Phase III trial of adjuvant vemurafenib therapy versus placebo for patients with resected cutaneous BRAF-mutant melanoma at high risk of recurrence will include treatment with interferon alpha.
 - True
 - False
- Common side effects associated with vemurafenib include _____.
 - Rash
 - Secondary epithelial skin cancer
 - Hyperkeratotic lesions
 - Photosensitivity reaction
 - All of the above
- Anti-PD-1 antibody is associated with _____.
 - Colitis
 - Autoimmune pneumonitis
 - Both a and b
 - Neither a nor b
- A recently published article by the National Cancer Institute demonstrated that patients who developed Grade 3 toxicities were more likely to respond to ipilimumab therapy than those without drug-induced toxicity.
 - True
 - False
- _____ is a small-molecule hedgehog inhibitor used in the treatment of adult patients with metastatic basal cell carcinoma.
 - Vismodegib
 - Ipilimumab
 - Trametinib
 - Interleukin-2
- Which of the following is a common vismodegib-related adverse event?
 - Ageusia
 - Muscle cramping
 - Both a and b
 - Neither a nor b